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RNA sequencingRecent evidence demonstrates the power of RNA sequencing (RNA-Seq) for identifying valuable and urgently need-
ed blood biomarkers and advancing both early and accurate detection of neurological diseases, and in particular
Parkinson's disease (PD). RNA sequencing technology enables non-biased, high throughput, probe-independent in-
spection of expression data and high coverage and both quantiﬁcation of global transcript levels as well as the de-
tection of expressed exons and junctions given a sufﬁcient sequencing depth (coverage). However, the analysis of
sequencing data frequently presents a bottleneck. Tools for quantiﬁcation of alternative splicing from sequenced li-
braries hardly exist at the present time, andmethods that supportmultiple sequencing platforms are especially lack-
ing. Here, we describe in details a whole RNA-Seq transcriptome dataset produced from PD patient's blood
leukocytes. The samples were taken prior to, and following deep brain stimulation (DBS) treatment while being
on stimulation and following 1 h of complete electrical stimulation cessation and from healthy control volunteers.
We describe in detail the methodology applied for analyzing the RNA-Seq data including differential expression
of long noncoding RNAs (lncRNAs).We also provide details of the corresponding analysis of in-depth splice isoform
data from junction and exon reads, with the use of the software AltAnalyze. Both the RNA-Seq raw (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42608) and analyzed data (https://www.synapse.org/#!Synapse:
syn2805267) may be found valuable towards detection of novel blood biomarkers for PD.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(SpeciﬁcationsOrganism/cell line/tissue Human/blood leukocytes
Sex Male
Sequencer or array type SOLiD-3
Data format Raw and analyzed (primary RNA-Seq analysis level).
Experimental factors Parkinson's disease pre-deep brain stimulation (DBS)
treatment, and post treatment on and off electrical
stimulation as well as age and gender-matched control
samples.eq).
. This is an open access article under thcontinued)
SpeciﬁcationsExperimental featurese CC BY-NC-ND license (httFrom each patient, 3 blood samples were taken: one day
prior to DBS neurosurgery which included bi-lateral im-
plantation of microelectrodes into the subthalamic nu-
cleus (upon hospitalization), and several weeks
post-DBS 1) while being on electrical stimulation and
following 1 h of electrical stimulation cessation. The
leukocytes were fractionated from each sample.Consent All the samples were taken under informed consent
and under the Hadassah Ethics committee approval.Sample source location Jerusalem, Israel, Human.Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42608
https://www.synapse.org/#!Synapse:syn2805267p://creativecommons.org/licenses/by-nc-nd/4.0/).
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Experimental design
Blood leukocyte samples from three PD patients were collected one
day prior to DBS treatment, and a few weeks later upon clinical
symptoms stabilization. Sampling occurred under turned on electri-
cal stimulation and following 1 h of electrical stimulation cessation
(which re-induced the disease motor symptoms). Samples were also
collected from age and gender matched apparently healthy control
(HC) volunteers (Fig. 1).
Materials and methods
Subject recruitment
Three PD patients and three matched control volunteers were
recruited to the study. All the participants signed informed consent
forms prior to inclusion. The samples were collected from the PD pa-
tients' pre- and post-bilateral sub-thalamic (STN)-DBS neurosurgery
while being on stimulation and following a short 1-hour of stimulation
cessation. All of the study volunteers that passed the study exclusion
criteria signed informed consent forms prior to inclusion in the study
(clinical parameters of the recruited volunteers are given under [1]).
To control for potential variability in the leukocyte expression proﬁles
that might stem from other factors (such as infections, or other dis-
eases), volunteers were assessed for their clinical overall background
and state up to 1 year earlier (e.g past hospitalizations, high fever)
and subsequently fulﬁlled detailed medical history questionnaires. Ex-
clusion criteria for participant patients included depression and past
and current DSM Axis I and II psychological disorders (SM), chronic in-
ﬂammatory disease, coagulation irregularities, previousmalignancies or
cardiac events, or any surgical procedure up to one year pre-DBS. Poten-
tial volunteers that did not fulﬁll these inclusion criteria were excluded
from the study. All patients went through bilateral STN-DBS electrode
implantation (Medtronics, USA) and were under dopamine replace-
ment therapy (DRT) both pre- and post-DBS (on signiﬁcantly reduced
dosage post-DBS, with t-test p b 0.01), the last medication administered
at least ﬁve hour pre-sampling. The clinical severity of the disease was
assessed by a neurologist using the Uniﬁed PD Rating Scale (UPDRS)
[2]. Controls were recruited among Hadassah hospital staff and re-
searchers at the Edmond J. Safra Campus (Jerusalem). All study volun-
teers underwent stringent ﬁltering prior to inclusion in the study. The
exclusion criteria for the healthy control volunteers included smoking,
chronic inﬂammatory diseases, drug/alcohol usage, major depression,
previous cardiac events, fever within up to 3 months prior to inclusion
in the study and past year hospitalizations.
Blood sample collection
To reduce expression proﬁle variability due to timedifferences in the
sample collection, blood collection was conducted within a ﬁxed rangeLeukoLOCK™ Total RNA 
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Fig. 1. General experimental ﬂow: blood samples from 3 Parkinson's disease (PD) patients pre-
complete electrical stimulation cessationwere collected aswell as from3 age- and gender-matc
was produced and cDNA library prepared for sequencing by SOLiD 3 system.of hours (10 AM–14 PM). The samples were collected in 9 ml blood
using 4.5 ml EDTA (anti-coagulant) tubes.
Leukocyte fractionation
The collected venous blood was ﬁltered using the LeukoLock frac-
tionation and stabilization kit (Ambion, Applied Biosystems, Inc., Foster
City, CA) up to 15 post-extraction minutes to enhance inspection accu-
racy. To ensure high RNA quality, the leukocyte-enriched samples were
immediately incubated in RNALater (Ambion) (http://www.affymetrix.
com/support/technical/technotes/blood_technote.pdf). Stabilized ﬁlters
and serum samples were stored at−80 °C.
RNA extraction
RNA extraction followed the manufacturer's (Life Technologies)
alternative protocol instructions for using the LeukoLock ﬁlters.
Brieﬂy, cells were ﬂushed (TRI-Reagent Ambion) into 1-bromo-3-
chloropropane-containing 15 ml tubes and centrifuged. 0.5 and
1.25 volumewater and ethanol were added to the aqueous phase. Sam-
ples were ﬁltered through spin cartridges, stored in pre-heated 150 μl
EDTA; RNA was quantiﬁed in Bioanalyzer 2100. Determination of RNA
quality and quantity was conducted using the Eukaryote Total
RNANano 6000 kit (Agilent). RNA was frozen and stored in −80 °C
immediately after production.
cDNA libraries preparation and sequencing
RNA quality was assessed by running the samples on Agilent RNA
6000 Nano-gels (#5067-1511). For each library Ribosomal RNA of 5 μg
total RNA was removed using Invitrogen's RiboMinus kit (#A10837-08)
and then samples were concentrated using the RiboMinus Concentration
Module (Invitrogen). Ribosomal RNA removal was veriﬁed by RNA 6000
Nano gel analysis. Library construction was conducted according to
SOLiD Whole Transcriptome Analysis Kit (PN4425680) protocol, frag-
mentation (by RNase-III) was veriﬁed on Agilent RNA 6000 Pico Kit
(#5067-1513) and 150 ng fragmented RNA was used for further proto-
cols. cDNA samples were run on 4% Agarose gels, 150–250 base pairs
(bp) sized fragments were cut and extracted using Qiagen Min-Elute
Gel-Extraction Kit (#28604), and gels were dissolved by intensive vortex
and not by heating. Librarieswere ampliﬁed for 12 cycles using bar-coded
primers supplied in SOLiD Transcriptome Multiplexing Kit (Ambion,
#4427046). Libraries were quantiﬁed using the Kapa ABI SOLiD Library
Quantiﬁcation Kit (KK4833) and diluted for ﬁnal analysis on Agilent
High Sensitivity DNA Kit (#5067-4626). 500 μM libraries were used for
emulsion PCR according to Applied Biosystems SOLiD-3 System Template
Bead Preparation Guide (4407421) to prepare for sequencing on the
SOLiD-3 platform.
The general workﬂow of RNA-Seq analysis is under Fig. 2.
Primary processing of SOLiD RNA-Seq reads
RNA-Seq reads (.csfasta ﬁles) and quality scores (.qual ﬁles) were
obtained using the SOLiD instrument software: SOLiD-3. SystemLibrary 
Consturction
(SOLiD protocol)
Library 
Quantification
Emulsion
PCR & Template
bead preperationn
ng
 each
Gel Purification 
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ytes, RNA extraciton and RNA-Seq library preparation 
Deep Brain Stimulation (DBS) and post-DBS on electrical stimulation and following 1 h of
hed healthy control (HC) volunteers. From each sample, The leukocyteswere ﬁltered, RNA
Fig. 2.Whole transcriptome sequencing on the produced libraries yielded .csfasta, .qual and .stat ﬁles for each sequenced sample. Mapping to the human genome (UCSC database) was
conducted through cloud computing to produce both exon and junction level quantiﬁcation ﬁles. AltAnalyze softwarewas used to analyze these ﬁles separately and combined and detect
high conﬁdence splice isoformalteration between the different clinical states. LongnoncodingRNAs (lncRNAs)were detected in the sequenced libraries throughmapping to theGENCODE
catalog (version 7), and differential expression analysis conducted for the lncRNAs using the Bioconductor project EdgeR program.
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image analysis, bead ﬁnding, quality metrics and color calls. The soft-
ware applications used to set and control data analysis included SOLiD
software suite under license agreement. The suit included: Instrument
Control Software (ICS), SOLiD Experimental Tracking System (SETS),
and SOLiD Analysis Tools (SAT) V3.0. Job management by the Job
Manager used the Corona-Lite v4.0 platform. Sequencing was run on
the Applied Biosystems SOLiD 3 System. Images of each cycle were
analyzed, data clustered and normalized. For each tag, a sequential
(sequence-ordered) set of color space calls was produced. Quality
metrics were produced through normalization. Two probe sets
were used to maximize the fraction of “mappable” ampliﬁed beads,
read length and sequencing throughput for sequencing of the 50-
bp reads. Five rounds of primers (A, B, C, D and E) were used to se-
quence template by ligation of di-base labeled probes. As the libraries
were size fragmented, the set of primers used was speciﬁc to the P1
Adaptor. For each library three types of raw data ﬁles were created:
.csfasta (the sequenced reads in color space), .qual and .stats. The qual-
ity values given in the .qual ﬁles (estimate of conﬁdence given for each
color call), q for a particular call, is mathematically related to its proba-
bility of error (p), and its SOLiD q values are similar for those generated
by Phred and the KB basecaller for capillary electrophoresis (described
in detail under [3]). The algorithm relies on training (calibration) to a
large set of control data and color calls for which the correct call is
known. In the SOLiD-3 system, the correct call is determined by map-
ping the read to a known reference sequence. Further details regarding
additional RNASeq analysis pipelines are detailed under [1].Secondary RNA-Seq analysis: mapping of RNA-Seq reads to exons and
junctions
The analysis stage included aligning the reads to the human ge-
nome — UCSC human genome version 19 February 2009 GRCh37
(the reference genome in this case, using the database ﬁle homo_
sapiens.GRCh37.56.dna.toplevel.fa) and generation of base space
sequences. Each library was mapped using the Mapreads function of
SOLiD™ BioScope™ (v1.3) cloud computing software (life technologies,
applied biosystems, Carlsbad, California). All the alignment and map-
ping were done on ordered genomes.Tertiary RNA-Seq analysis: exon and junction expression quantiﬁcation
Junction mapping was conducted using the Bioscope splice junction
extractor tool through cloud computing and exon level mapping con-
ducted using the count tag tool. 2 mappings were run for each sample:
1) exon level — to receive exon quantiﬁcation and 2) junction level
quantiﬁcation. The output of this step included .gff and .sam ﬁles. For
both cases, merging of count reads that employed discontinuous wordpattern search algorithmswas performed. The scripts used for mapping
are also included in the public Synapse depository.
De-novo splicing prediction, poly-A predictions and UCSC exon annotation
Following the identiﬁcation of all the transcript structural event types
byparsing of both the Ensembl andUCSCdatabases, the cases of intron re-
tention were identiﬁed ﬁrst by searching for regions that span two adja-
cent exons in at least one additional transcript for each gene. The
remaining exons were clustered based on overlapping genomic coordi-
nates (e.g. alternate 5′ ends or 5′ start-sites). Each exon was annotated
as corresponding to exon block and region number within the corre-
sponding transcript. All possible pair-wise transcript comparisons
for each gene were then performed to identify exon pairs that show evi-
dence of alternative exon-cassettes, alternative 3′ or 5′ splice-sites or
alternative-N or -C terminal exons. All transcript exon pairs were consid-
ered (except for those adjacent to a retained intron) by comparing the
exon block-ID and region-IDs of an exon and its neighboring exons to
the exon blocks and regions in the compared transcripts, and a custom
heuristic assigned the appropriate annotation based on these transcript
comparisons. This process is repeated when importing RNA-Seq reads
to identify novel splicing events. In addition to all de-novo splicing anno-
tations, additional splicing annotations (e.g., alternative cassette-exon, al-
ternative promoter) are imported from the UCSC genome database and
linked to existing exon blocks and regions based on genomic coordinate
overlap. We have further incorporated alternative Poly-A predictions
using the polyA database [4]. Further details are given under AltAnalyze
online documentation (www.altanalyze.org) [5].
Finding alternatively spliced exons
Through AltAnalyze, we analyzed exons and junctions separately
as well as combined these results to ﬁnd high conﬁdence alternative-
ly spliced exons and differentially expressed genes. We used the
splicing index method (originally developed for exon arrays),
ASPIRE (originally developed for splice junction arrays [6]) as well
as linear regression calculations (originally developed for splice
junction arrays) on pairs of reciprocal junction pairs (that can either
include or exclude the exon found in between them) [7]. The value cal-
culated by splicing index is the change in exon-inclusion (delta I, dI, or
splicing index fold change).
NI(probeset_i) = PIGE
 
where PI is the intensity of the exon and GE is
the gene level expression value in that sample group to obtain a normal-
ized intensity (NI) for each exon. Comparison of the log2 values of theNI
between two sample groups arrives at a splicing-index (SI) value [8,9].
SI probeset ið Þ ¼ log2
NI PIð Þsample1
NI PIð Þsample2
 
:
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junction, an estimate of overall junction ratio differences is calculated by
comparing the expression of the two reciprocal junctions being mea-
sured (e.g., E1–E2 versus E1–E3) (non-log), between the baseline and
experimental groups. These ASPIRE dI can be calculated from the com-
parison of inclusion and exclusion junctions or an inclusion exon and an
exclusion junction. The linear regression algorithm (based on previous-
ly described approach [7]) also uses the same reciprocal exon/junction
features as ASPIRE. To derive the slope for each of the two biological
conditions (control and experimental), the constitutive corrected ex-
pression of all samples for both reciprocal junctions is plotted against
each other to calculate a slope for each of the two biological groups
using the least squaresmethod. In each case, the slope is forced through
the origin of the graph (model=y ~ x− 1 as opposed to y ~ x). Theﬁnal
linear regression score is the log2 ratio of the slope of the baseline group
divided by the experimental group. This ratio is analogous to a log2 fold
change, where 1 is equivalent to a 2-fold change.
Analysis of protein binding domain composition
Identiﬁcation of protein domains that were predictably disrupted by
alternative splicing changes in each clinical state was conducted
through AltAnalyze. To identify alternative protein domains, RNA-Seq
andmicroarrays probe-sets sequenceswere used to identify which pro-
teins align to, or are missing from, transcripts for each disease, treat-
ment or stimulation cessation spliced gene transcript, and speciﬁcally
for each spliced isoform.
Quantiﬁcation and differential expression analysis of long non-coding RNAs
(lncRNAs)
As part of the ENCODE project, the GENCODE consortium manually
curated 9277 human lncRNAs. The human long non-coding RNA data-
base bed coordinates of Gencode (version 7) [10] were downloaded
from the GENCODE lncRNA data page of the CRG Bioinformatics
and Genomics Group [http://big.crg.cat/bioinformatics_and_genomics/
lncrna_data] and complemented with other non-coding transcript
information available from the EnsEMBL BioMart version 0.7 query
interface to the EnsEMBL Genes 72 — GRCh37.p11 database (www.
ensembl.org). Genome coordinates in .BED format (corresponding to
the mapped reads) used the Lifescope Lifetech 2.5.1 software and
UCSC hg19 masked reference database as obtained by the original
.sam ﬁles with SAMtools, SAMtools view and bedtools bamToBed.
These read bed ﬁles were intersected with the genome coordinates of
the above-mentioned lncRNAs using the bedtools intersectBed pro-
gram, requiring a 90% overlap of each sequence read with a target
lncRNA. Lists of sequence tags corresponding to lncRNAs were obtained
by intersection of the bed tools. For differential expression analysis, the
read count information of all of the detected lncRNAs was ﬁrst ﬁltered.
LncRNAs that did not present read count in N3 libraries, or did not exist
in EnsEMBL were ﬁltered out. The remaining lncRNAs (overall, 6430
leukocyte expressed lncRNAs) were analyzed using the Bioconductor
edge-R [11] software (version 3.0.1) to detect differential expression
between the patients in different clinical stages and the control volun-
teers. This analysis module is particularly suitable to use on smallnumbers of replicate samples. The results were annotated using the
BioMart integrated annotation database query interface [12] using the
human genome reference consortium assembly build version 37
(GRch37, hg19) and GENCODE version 7.
Biological pathways analysis
Gene Ontology (GO)-Elite pathway analysis [13] was conducted
through AltAnalyze program, on the analyzed output result ﬁles of the
detected splice events at both the junction and exon levels as well as
the David tool EASE [14].
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